Patients with mental health conditions denied access to ‘best available’ stop smoking treatments

Patients with mental health conditions denied access to ‘best available’ stop smoking treatments

University of Bath Press Release

A new study suggests that rethinking prescriptions for smokers with mental health conditions wishing to kick the habit could have a significant impact.

A new study from researchers at the Universities of Bristol and Bath suggests that doctors should rethink which drugs they prescribe to help smokers with mental health conditions kick the habit.  

Their results highlight that the most effective drug at helping individuals to stop smoking is less likely to be prescribed to people with mental health conditions.

People with mental health conditions, such as anxiety or depression, are twice as likely to smoke compared to the general population. They tend to smoke more cigarettes per day, are more heavily addicted, and are more likely to relapse when they try to quit. In addition, whereas smoking rates in the UK have declined over recent decades, smoking rates have changed relatively little for people with mental health conditions.

Most smokers wishing to quit are prescribed two common smoking cessation drugs: nicotine replacement therapy (NRT) and varenicline. Recent randomized trials and observational studies have found that patients prescribed varenicline are more likely to stop smoking compared to those prescribed NRT. There have been concerns around the psychological safety of varenicline, with doctors more reluctant to prescribe the drug to smokers with mental health conditions. In fact, the best evidence shows that varenicline is not associated with worse mental health outcomes.

This study, published today [Wednesday 7 July] in the journal Nicotine & Tobacco Research, compares rates by which patients prescribed NRT* and varenicline** succeed in giving up, and what effects the drugs have on individual’s mental health.

Drawing on data from over 200,000 smokers, the study compares outcomes for patients with and without mental health conditions prescribed both types of drug. The results highlight that:

  • Compared to smokers without mental health conditions, smokers with these conditions were 31% less likely to be prescribed varenicline than NRT.
  • Smokers with mental health conditions who were prescribed varenicline were 19% more likely to have successfully quit at 2-years follow-up, than NRT.
  • Varenicline is more effective than NRT in helping patients stop smoking and there was little ‘evidence that varenicline was adversely associated with poorer mental health outcomes’. In general, varenicline was not associated with worse mental health outcomes.

Lead researcher, Dr Gemma Taylor from the University of Bath’s Addiction & Mental Health Group with the Department of Psychology explains: “Smoking is still the world’s leading cause of preventable illness and death. One in every two smokers will die because of their addiction unless they quit. Yet, whilst smoking rates have declined over recent decades for the general population, prevalence has not shifted to the same extent in people with mental health conditions who still face the burden of smoking related mortality and morbidity and lower life expectancy.

“This study is about addressing this public health challenge to see whether assumptions about prescriptions could be challenged to give patients wishing to quit a better chance of success. Our results, in combination with results from clinical trials, suggest that doctors should rethink prescription practice in view of the benefits varenicline could bring to help those with mental health conditions stop smoking. Stopping smoking has clear physical health benefits, and there is growing evidence that stopping smoking is associated with better mental health too.”

The research team conducted the study using electronic medical records from 654 general practices in England from 2006-15 via the Clinical Practice Research Database.

Comparing patients’ success in quitting smoking using either NRT or varenicline, they focused on rates by which patients with mental health conditions gave up at 3, 6 and 9 month windows, as well at 1, 2 and 4 years after first prescription.

The team also observed that across all patients, NRT and varenicline prescribing declined overtime. This could be because NHS Stop Smoking Services are being decommissioned from primary care.

Professor Ann McNeill, Professor of Tobacco Addiction, King’s College London and co-Chair of the Mental Health and Smoking Partnership said: “People with mental health conditions are more likely to smoke and smoke heavily than those without, and this contributes to them dying much earlier. Doctors should therefore be pulling out all the stops to help these smokers to quit, but this research involving nearly 80,000 smokers, shows that this is not happening.

“Smokers with mental conditions are less likely to be prescribed varenicline than nicotine replacement therapy, than those without mental health conditions, despite the authors finding varenicline to be more effective and generally associated with better mental health outcomes.”

The research was approved by the Independent Scientific Advisory Committee and funded by Global Research Awards for Nicotine Dependence (GRAND), an independently reviewed competitive grants program supported by Pfizer.

The first author’s salary was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme [project number 14/49/94] during the conduct of this research. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the article.


For further information, please contact Andy Dunne in the University of Bath Press Office on +44 (0)1225 386319 or email


* Nicotine replacement therapy (NRT), a medication which provides patients with a low level of nicotine without the tar, carbon monoxide and other poisonous chemicals present in tobacco smoke. NRT commonly comes in the form of skin patches, chewing gum and inhalers. According to the NHS, it can help reduce unpleasant withdrawal effects such as bad moods and cravings.

**Varenicline, a medication that works in two ways both reducing cravings for nicotine like NRT, but also blocking the rewarding and reinforcing effects of smoking. Varenicline is taking in the form of tablets and treatment usually lasts around 12 weeks. According to the NHS, evidence suggests varenicline is the most effective medication for helping people to stop smoking.

University of Bath

The University of Bath is one of the UK’s leading universities both in terms of research and our reputation for excellence in teaching, learning and graduate prospects.

The University is rated Gold in the Teaching Excellence Framework (TEF), the Government’s assessment of teaching quality in universities, meaning its teaching is of the highest quality in the UK.

In the Research Excellence Framework (REF) 2014 research assessment 87 per cent of our research was defined as ‘world-leading’ or ‘internationally excellent’. From developing fuel efficient cars of the future, to identifying infectious diseases more quickly, or working to improve the lives of female farmers in West Africa, research from Bath is making a difference around the world. Find out more: